Publications

    Patents and patent applications

  1. Collagen receptor I-domain binding modulators
  2. Sulphonamide derivatives
  3. Novel compounds and their use in therapy
  4. Benzo (4,5) thieno (2,3-D) pyrimidin-4-ones and their use in therapy
  5. Crystalline vap-1 and uses thereof, patent no: US 7,499,847 B2
  6. Compounds and their use in therapy, patent no: US 7,524,853 B2
  7. Novel substituted thiophenepyrimidinone derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase, patent no: EP1828197 (B1)
  8. Research papers (members of our research group are underlined)

    2018
  9. Juvonen RO, Ahinko M, Huuskonen J, Raunio H, Pentikäinen OT. Development of New Coumarin-Based Profluorescent Substrates for Human Cytochrome P450 Enzymes. Xenobiotica. Accepted.
  10. Rauhamäki S, Postila P, Lätti S, Niinivehmas S, Multamäki E, Liedl K, Pentikäinen OT. Discovery of Retinoic Acid-Related Orphan Receptor γt Inverse Agonists via Docking and Negative Image-Based Screening. ACS Omega, 2018, 3: 6259–6266.OpenAccess
  11. Hopkins D, Envall T, Poikela N, Pentikäinen OT, Kankare M. Effect of cold acclimation and dsRNA injections on Gs1l gene splicing in Drosophila montana. Scientific Reports, 2018, 8: 7577.Access
  12. Niinivehmas S, Postila PA, Rauhamäki S, Manivannan E, Kortet S, Ahinko M, Huuskonen P, Nyberg N., Koskimies P, Lätti S, Multamäki E, Juvonen RO, Raunio H, Pasanen M, Huuskonen J, Pentikäinen OT. Blocking oestradiol synthesis pathways with potent and selective coumarin derivatives. Journal of Enzyme Inhibition and Medicinal Chemistry. 2018, 33:743-754.Access
  13. Kurkinen S, Niinivehmas S, Ahinko M, Lätti S, Pentikäinen OT, Postila P. Improving Docking Performance Using Negative Image-Based Rescoring. Frontiers in Pharmacology. 2018, 9:260, Access.
  14. Rauhamäki S, Postila PA, Niinivehmas S, Kortet S, Schildt E, Pasanen Mi, Manivannan E, Ahinko M, Koskimies P, Nyberg N, Huuskonen P, Multamäki E, Pasanen Ma, Juvonen RO, Raunio H, Huuskonen J, Pentikäinen OT. Structure-Activity Relationship Analysis of 3-phenylcoumarin-Based Monoamine Oxidase B Inhibitors. Frontiers in Chemistry, 2018, https://doi.org/10.3389/fchem.2018.00041
  15. Juvonen RO, Rauhamäki S, Kortet S, Niinivehmas S, Troberg J, Petsalo A, Huuskonen J, Raunio H, Finel M, Pentikäinen OT. Molecular Docking-Based Design and Development of a Highly Selective Probe Substrate for UDP-glucuronosyltransferase 1A10. Molecular Pharmaceutics. 2018, 15: 923-933.
  16. 2017
  17. Kaźmierczak, A; Kusy, D; Niinivehmas, S; Gmach, J; Joachimiak, Ł; Pentikäinen, OT; Gendaszewska-Darmach, E; Blazewska, K. Identification of the privileged position in the imidazo[1,2-a]pyridine ring of phosphonocarboxylates for development of Rab geranylgeranyl transferase (RGGT) inhibitors. Journal of Medicinal Chemistry, 2017, 60:8781-8800.
  18. Seppälä J, Bernardi RC, Haataja T, Hellman M, Pentikäinen OT, Schulten K, Permi P, Ylänne J, Pentikäinen U. Scientific Reports, 2017, 7: 4218.
  19. 2016
  20. Lätti S, Niinivehmas S, Pentikäinen OT. Rocker: Open source, easy-to-use tool for AUC and enrichment calculations and ROC visualization. Journal of Cheminformatics, 2016, 8:45.
  21. Puurtinen M, Elo M, Jalasvuori M, Kahilainen A, Ketola T, Kotiaho JS, Monkkonen M, Pentikainen OT. Temperature-dependent mutational robustness can explain faster molecular evolution at warm temperatures, affecting speciation rate and global patterns of species diversity. Ecography 2016, 39, 1025-1033.
  22. Niinivehmas SP, Manivannan E, Rauhamäki S, Huuskonen J, Pentikäinen OT. Identification of estrogen receptor alpha ligands with virtual screening techniques. Journal of Molecular Graphics and Modeling. 2016, 64: 30-39.
  23. Yasuda T, Al Sazzad MA, Jäntti NZ, Pentikäinen OT, Slotte JP. The Influence of Hydrogen Bonding on Sphingomyelin/Colipid Interactions in Bilayer Membranes. Biophysical Journal. 2016, 110: 431-440.
  24. 2015
  25. Virtanen SI, Niinivehmas SP, Pentikäinen OT.. Case-specific performance of MM-PBSA, MM-GBSA, and SIE in virtual screening. Journal of Molecular Graphics and Modeling. 2015, 62: 303-318.
  26. Niinivehmas SP, Salokas K, Lätti S, Raunio H, Pentikäinen OT. Ultrafast protein structure-based virtual screening with Panther. Journal of Computer-aided Molecular Discovery, 2015, 29: 989-1006.
  27. Shubina V, Niinivehmas S, Pentikäinen OT. Reliability of Virtual Screening Methods in Prediction of PDE4B-inhibitor activity. Current Drug Discovery Technologies, 12: 117-126.
  28. Raunio H, Kuusisto M, Juvonen RO, Pentikäinen OT. Modeling of interactions between xenobiotics and cytochrome P450 (CYP) enzymes. Frontiers in Pharmacology, 2015, 6: 123.
  29. Juvonen RO, Kuusisto M, Fohrgrup C, Pitkänen MH, Nevalainen TJ, Auriola S, Raunio H, Pasanen M, Pentikäinen OT. Inhibitory effects and oxidation of 6-methylcoumarin, 7-methylcoumarin and 7-formylcoumarin via human CYP2A6 and its mouse and pig orthologous enzymes. Xenobiotica, 11: 1-11.
  30. 2014
  31. Sethi R, Seppälä J, Tossavainen H, Ylilauri M, Ruskamo S, Pentikäinen OT, Pentikäinen U, Permi P, Ylänne J. A Novel Structural Unit in the N-Terminal Region of Filamins. Journal of Biological Chemistry, 2014, 289: 8588-8598.
  32. Boratynski Z, Melo-Ferreira J, Berto S, Koskela E, Alves P, Pentikäinen O, Tarroso P, Ylilauri M, Mappes T. Molecular and ecological signs of mitochondrial adaptation: consequences for introgression? Heredity, 2014, 113: 277-286.
  33. 2013
  34. Ylilauri M, Pentikäinen OT. MMGBSA As a Tool To Understand the Binding Affinities of Filamin–Peptide Interactions. Journal of Chemical Information and Modeling, 2013, 53, 2626–33
  35. Ylilauri M, Mattila E, Nurminen EM, Käpylä J, Niinivehmas SP, Määttä JA, Pentikäinen U, Ivaska J, Pentikäinen OT. Molecular mechanism of T-cell protein tyrosine phosphatase (TCPTP) activation by mitoxantrone. BBA - Protein and Proteomics, 2013, 1834: 1988-1997
  36. Maula T, Isaksson JE, García-Linares S, Niinivehmas S, Pentikäinen OT, Kurita M, Yamaguchi S, Yamamoto T, Katsumura S, Gavilanes JG, Martínez-del-Pozo Á, Slotte JP. 2NH and 3OH are crucial structural requirements in sphingomyelin for sticholysin II binding and pore formation in bilayer membranes, BBA - Biomembranes, 2013, 1828: 1390-95
  37. 2012
  38. Ylilauri M, Pentikäinen OT. Structural Mechanism of N-Methyl-D-Aspartate Receptor Type 1 Partial Agonism. PLoS One, 2012, 7: e47604
  39. Sergelius C, Niinivehmas S, Maula T, Kurita M, Yamaguchi S, Yamamoto T, Katsumura S, Pentikäinen OT, Slotte JP. Structure-activity relationship of sphingomyelin analogs with sphingomyelinase from Bacillus cereus. Biochimica et Biophysica Acta - Biomembranes, 2012, 1818: 474-80
  40. Nissinen L, Koivunen J, Käpylä J, Salmela M, Nieminen J, Jokinen J, Sipilä K, Pihlavisto M, Pentikäinen OT, Marjamäki A, Heino J. Novel alpha2beta1 integrin inhibitors reveal that integrin binding to collagen under shear stress conditions does not require receptor preactivation. Journal of Biological Chemistry, 2012, 287: 44694-702
  41. 2011
  42. Koivunen JT, Nissinen L, Käpylä J, Jokinen J, Pihlavisto M, Marjamäki A, Heino J, Huuskonen J, Pentikäinen OT. Fluorescent small molecule probe to modulate and explore alpha2beta1 integrin function. Journal of the American Chemical Society, 2011, 133, 14558-14561.
  43. Koivunen J. Discovery of a2b1 integrin ligands: Tools and drug candidates for cancer and thrombus, PhD-thesis
  44. Koivunen JT, Nissinen L, Juhakoski A, Pihlavisto M, Marjamäki A, Huuskonen J, Pentikäinen OT.Blockage of Collagen Binding to Integrin alpha2beta1: Structure-activity Relationship of Protein-protein Interaction Inhibitors, Medicinal Chemistry Communications, 2011, 2:764-770.Journal page
  45. Niinivehmas SP*, Virtanen SI*, Lehtonen JV, Postila PA, Pentikäinen OTComparison of Virtual High-throughput Screening Methods for the Identification of Phosphodiesterase-5 Inhibitors, Journal of Chemical Information and Modeling, 2011, 51: 1353-1363.(*equal contribution)
  46. Postila PA, Ylilauri M, Pentikäinen OT Full and Partial Agonism of Ionotropic Glutamate Receptors Indicated by Molecular Dynamics Simulations, Journal of Chemical Information and Modeling, 2011, 51:1037–1047.
  47. Nurminen E. Rational Drug Discovery, PhD-thesis
  48. Nurminen EM, Pihlavisto M, Lázár L, Pentikäinen U, Fülöp F, Pentikäinen OT. Novel hydrazine molecules as tools to understand the flexibility of vascular adhesion protein-1 ligand-binding site . towards more selective inhibitors, Journal of Medicinal Chemistry, 2011, 54: 2143–2154.
  49. 2010
  50. Postila P. Dynamics of the ligand-binding domains of ionotropic glutamate receptors. PhD-thesis
  51. Coleman SK, Möykkynen T, Hinkkuri S, Vaahtera L, Korpi ER, Pentikäinen OT, Keinänen K. Ligand-binding domain determines ER exit of AMPA receptors, Journal of Biological Chemistry, 2010, 285: 36032-36039
  52. Li C, Yu S, Nakamura F, Pentikäinen OT, Singh N, Yin S, Xin W, Sy M-S. Pro-prion binds filamin A facilitating its interaction with integrin beta1 and contributes to melanomagenesis, Journal of Biological Chemistry, 2010, 285: 30328-30339.
  53. Nurminen EM, Pihlavisto M, Lazar L, Szakonyi Z, Pentikäinen, U, Fulop, F, Pentikäinen, OT. Synthesis, in vitro activity, and three-dimensional quantitative structure-activity relationship of novel hydrazine inhibitors of human Vascular Adhesion Protein-1, Journal of Medicinal Chemistry, 2010, 53: 6301–6315.
  54. Nevo J, Mai A, Pellinen T, Pentikäinen OT, Heikkilä P, Lundin J, Joensuu H, Bono P, Ivaska J. Mammary derived growth inhibitor (MDGI) interacts with integrin alpha-subunits and suppresses integrin activity and invasion, Oncogene, 2010, 29: 6452-6463
  55. Virtanen SI, Pentikäinen OT. Efficient Virtual Screening Using Multiple Protein Conformations Described as Negative Images of the Ligand-Binding Site. Journal of Chemical Information and Modeling, 2010, 50: 1005–1011.
  56. Playford MP*, Nurminen E*, Pentikäinen OT, Milgram S, Hartwig JH, Stossel TP, Nakamura F. The cystic fibrosis transmembrane conductance regulator interacts with multiple IG domains of filamin A. Journal of Biological Chemistry, 285: 17156-17165.
  57. Postila P, Swanson GT, Pentikäinen OT. Exploring kainate receptor pharmacology using molecular dynamics simulations. Neuropharmacology, 2010, 58: 515-527.
  58. Nissinen L*; Pentikäinen OT*, Jouppila A*, Käpylä J, Ojala M, Nieminen J, Lipsanen A, Lappalainen H, Eckes B, Johnson MS, Lassila R, Marjamäki A, Heino J. A small molecule inhibitor of integrin alpha2beta1 introduces a new strategy for antithrombotic therapy. Thrombosis and Haemostasis, 2010, 103: 387-397
  59. Lash-van Wyhe LL, Postila PA, Tsubone K, Sasaki M, Pentikäinen OT, Sakai R, Swanson GT. Pharmacological activity of C10-substituted analogs of the high-affinity kainate receptor agonist dysiherbaine. Neuropharmacology, 2010, 58: 640-649.
  60. 2009
  61. Nakamura F, Heikkinen O, Pentikäinen OT, Osborn TM, Kasza KE, Weitz DA, Kupiainen O, Permi P, Kilpeläinen I, Ylänne J, Hartwig JH, Stossel TP. Molecular Basis of Filamin A-FilGAP Interaction and Its Impairment in Congenital Disorders Associated with Filamin A Mutations, PLoS One, 2009;4(3):e4928.
  62. Frydenvang K, Lash LL, Naur P, Postila PA, Pickering DS, Smith CM, Gajhede M, Sasaki M, Sakai R, Pentikäinen OT, Swanson GT, Kastrup JS. Full domain closure of the ligand-binding core of the ionotropic glutamate receptor iGluR5 induced by the high-affinity agonist dysiherbaine and the functional antagonist MSVIII-19, J. Biol. Chem. 2009, 284:14219-29.
  63. 2008
  64. Pentikäinen U, Pentikäinen OT, Mulholland AJ. Cooperative symmetric to asymmetric conformational transition of the apo-form of scavenger decapping enzyme revealed by simulations. Proteins: Structure, Function, and Bioinformatics, 2008, volume 70, pages: 498-508 DOI: 10.1002/prot.21540
  65. Lash LL, Sanders JM, Akiyama N, Shoji M, Postila P, Pentikäinen OT, Sasaki M, Sakai R, and Swanson GT. Novel analogs and stereoisomers of the marine toxin neodysiherbaine with specificity for kainate receptors. Journal of Pharmacology and Experimental Therapeutics, 2008, volume 324, pages: 484-496.
  66. 2007
  67. Dolman NP, More JCA, Alt A, Pentikäinen OT, Glasser CR, Bleakman D, Mayer ML, Collingridge GL, Jane DE. Synthesis and Pharmacological Characterization of N3-Substituted Willardiine Derivatives: Role of the Substituent at the 5-Position of the Uracil Ring in the Development of Highly Potent and Selective GLUK5 Kainate Receptor Antagonists, Journal of Medicinal Chemistry, 2007, volume 50, pages: 1558-1570.
  68. Käpylä J*, Pentikäinen OT*, Nyrönen T, Nissinen L, Lassander S, Jokinen J, Lahti M, Marjamäki A, Johnson MS, Heino J. A small molecule designed to target MIDAS in the alpha2I domain inhibits integrin function. Journal of Medicinal Chemistry, 2007, volume 50, pages: 2742-2746
  69. Lad Y, Kiema T, Jiang P, Pentikäinen OT, Coles CH, Campbell ID, Calderwood DA, Ylänne J. Structure of three tandem filamin domains reveals auto-inhibition of ligand binding. EMBO Journal, 2007, volume 26, pages: 3993-4004.
  70. Postila PA, Pentikäinen OT. Glutamate receptors: structure-function relationship and ligand discovery. CSC report on computational science in Finland 2006-2007, Eds: Sillanpää et al., 2007, pages: 105-108.
  71. 2006
  72. Messinger J, Hirvelä L, Husen B, Kangas L, Koskimies P, Pentikäinen O, Saarenketo P, Thole H. New inhibitors of 17beta-hydroxysteroid dehydrogenase type 1, 2006, Molecular and Cellular Endocrinology, 2006, volume 248, pages: 192-198.
  73. Pentikäinen U*, Settimo L*, Johnson MS and Pentikäinen OT. Subtype selectivity and flexibility of ionotropic Glutamate Receptors upon antagonist ligand binding. Organic & Biomolecular Chemistry, 2006, volume 4, pages: 1058-1070.
  74. Sanders JM, Pentikäinen OT, Settimo L, Pentikäinen U, Shoji M, Sasaki M, Sakai R, Johnson MS and Swanson GT. Determination of binding site residues responsible for the subunit selectivity of novel marine-derived compounds on kainate receptors. Molecular Pharmacology, 2006, volume 69, pages: 1849-1860.
  75. Marttila-Ichihara F, Smith DJ, Stolen C, Yegutkin G, Elima K, Mercier N, Merinen M, Kiviranta R, Pihlavisto M, Alaranta S, Pentikäinen U, Pentikäinen OT, Fülöp F, Jalkanen S and Salmi M. Vascular amine oxidases are needed for leukocyte extravasation into inflamed joints in vivo. Arthritis & Rheumatism, 2006, volume 54, pages: 2852-2862.
  76. Repo S, Paldanius TA, Hytönen VP, Nyholm TKM, Halling KK, Huuskonen J, Pentikäinen OT, Rissanen K, Slotte JP, Airenne TT, Salminen TA, Kulomaa MS and Johnson MS. Binding properties of HABA-type azo derivatives to avidin and avidin-related protein 4. Chemistry & Biology, 2006, volume 13, pages:1029-1039.
  77. 2005
  78. Sanders JM, Ito K, Settimo L, Pentikäinen OT, Shoji M, Sasaki M, Johnson MS, Sakai R, and Swanson GT. Divergent pharmacological activity of novel marine-derived excitatory amino acids on glutamate receptors, Journal of Pharmacology and Experimental Therapeutics, 2005, volume 314, pages: 1068-1078. See also cover caption!
  79. Riikonen R, Matilainen H, Rajala N, Pentikäinen O, Johnson M, Heino J and Oker-Blom C. Functional Display of an alpha2 Integrin-Specific Motif (RKK) on the Surface of Baculovirus Particles, Technology in Cancer Research and Treatment, 2005, volume 4, pages: 437-446.
  80. 2004
  81. Nymalm Y, Puranen S, Nyholm T, Käpylä J, Pentikäinen OT, Airenne TT, Kidron H, Kankare J, Johnson MS, Slotte JP, Johnson MS, Salminen TA. Structural changes in the alpha1I domain of the human integrin a1b1 upon peptide binding. Journal of Biological Chemistry, 2004, volume 279, pages: 7962-7970.
  82. Karisola P, Mikkola J, Kalkkinen N, Airenne KJ, Laitinen O, Repo S, Pentikäinen OT, Reunala T, Turjanmaa K, Johnson MS, Palosuo T, Kulomaa MS, Alenius H. Design of a pilot molecule with reduced allergenicity for immunotherapy of latex allergy by co-mutation of six amino acid residues on the conformational IgE epitopes of hevein (Hev b 6.02). Journal of Immunology, 2004, volume 172, pages: 2621-2628.
  83. Hytönen VP, Nyholm TKM, Pentikäinen OT, Vaarno J, Porkka EJ, Nordlund HR, Johnson MS, Slotte JP, Laitinen OH, Kulomaa MS. Chicken avidin related protein 4/5 shows superior heat stability when compared to avidin, Journal of Biological Chemistry, 2004, volume 279, pages: 9337-9343.
  84. Moretti L*, Pentikäinen OT*, Settimo L, Johnson MS. Model structures of the N-methyl-D-aspartate receptor subunit NR1 explain the molecular recognition of agonist and antagonist ligands, Journal of Structural Biology, 2004, volume 145, pages: 205-215.
  85. Lehtonen JV, Rantanen V-V, Still D-J, Ekholm J, Björklund D, Iftikhar Z, Huhtala M, Jussila A, Jaakkola J, Pentikäinen OT, Nyrönen T, Salminen TA, Gyllenberg M and Johnson MS. BODIL: a molecular modeling environment for structure-function analysis and drug discovery, Journal of Computer-Aided Molecular Design, 2004, volume 18, pages: 401-419.
  86. 2003
  87. Zhang W-M, Käpylä J, Puranen JS, Knight CG, Tiger CF, Pentikäinen OT, Johnson MS, Farndale RW, Heino J, Gullberg D. alpha11beta1 integrin recognizes the GFOGER sequence in interstitial collagens, Journal of Biological Chemistry, 2003, volume 278, pages: 7270-7277.
  88. Pentikäinen OT, Settimo L, Keinänen K, Johnson MS. Selective agonist binding of AMPA and kainate receptors, Biochemical Pharmacology, 2003, volume 66, pages: 2413-2425.
  89. Pentikäinen OT. Modeling of protein-ligand interactions: Integrin I-domains and ionotropic glutamate receptors. Ph.D.-thesis.
  90. 2002
  91. Ollila F, Pentikäinen OT, Forss S, Johnson MS, Slotte JP. Characterization of Bile Salt/Cyclodextrin Interactions Using Isothermal Titration Calorimetry. Langmuir, 2002, volume 17, pages 7107-7111.
  92. Karisola P, Alenius H, Mikkola J, Kalkkinen N, Helin J, Pentikäinen OT, Repo S, Reunala T, Turjanmaa K, Johnson MS, Palosuo T, Kulomaa MS. The major conformational IgE-binding epitopes of hevein (Hev b6.02) are identified by a novel chimera-based allergen epitope mapping strategy. Journal of Biological Chemistry, 2002, volume 277, pages:22656-22661.
  93. Laitinen OH, Hytönen VP, Ahlroth MK, Pentikäinen OT, Gallagher C, Nordlund HR, Ovod V, Marttila AT, Porkka E, Heino S, Johnson MS, Airenne KJ, Kulomaa MS. Chicken avidin-related proteins show altered biotin-binding and physico-chemical properties as compared with avidin. Biochememical Journal, 2002, volume 363, pages: 609-617.
  94. Lampinen M, Settimo L, Pentikäinen OT, Jouppila A, Mottershead DG, Johnson MS, Keinänen K. Discrimination between agonists and antagonists by the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid-selective glutamate receptor. A mutation analysis of the ligand-binding domain of GluR-D subunit. Journal of Biological Chemistry, 2002, volume 277, pages: 41940-41947.
  95. Nymalm Y, Kravchuk Z, Salminen T, Chumanevich AA, Dubrovitsky AP, Kankare J, Pentikäinen O, Lehtonen J, Arosio P, Martsev S, Johnson MS. Antiferritin VL homodimer binds human spleen ferritin with high specificity. Journal of Structural Biology, 2002, volume 138, pages: 171-186.
  96. Jouppila A, Pentikäinen OT, Settimo L, Nyrönen T, Haapalahti J-P, Lampinen M, Mottershead D, Johnson MS, Keinänen K. Determinants of antagonist binding at the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor: Role of the conserved Arg-507 and Glu-727 residues. European Journal of Biochemistry, 2002, volume 269, pages: 6261-6270.
  97. 2001
  98. Tulla M, Pentikäinen OT, Viitasalo T, Käpylä J, Impola U, Nykvist P, Nissinen L, Johnson MS, Heino J. Selective binding of collagen subtypes by integrin alpha1I, alpha2I, and alpha10I domains. Journal of Biological Chemistry, 2001, volume 276, pages: 48206-48212.
  99. 2000
  100. Käpylä J, Ivaska J, Riikonen R, Nykvist P, Pentikäinen O, Johnson M, Heino J. Integrin alpha(2)I domain recognizes type I and type IV collagens by different mechanisms. Journal of Biological Chemistry, 2000, volume 275, pages: 3348-3354.
  101. 1999
  102. Ivaska J, Käpylä J, Pentikäinen O, Hoffrén AM, Hermonen J, Huttunen P, Johnson MS, Heino J. A peptide inhibiting the collagen binding function of integrin alpha2I domain. Journal of Biological Chemistry, 1999, volume 274, pages:3513-3521.
  103. Huhtala MT*, Pentikäinen OT*, Johnson MS. A dimeric ternary complex of FGFR [correction of FGFR1], heparin and FGF-1 leads to an 'electrostatic sandwich' model for heparin binding. Structure with Folding and Design, 1999, volume 15, pages: :699-709.
  104. Pentikäinen O, Hoffrén AM*, Ivaska J*, Käpylä J*, Nyrönen T*, Heino J, Johnson MS. "RKKH" peptides from the snake venom metalloproteinase of Bothrops jararaca bind near the metal ion-dependent adhesion site of the human integrin alpha(2) I-domain. Journal of Biological Chemistry, 1999, volume 274, pages: 31493-31505.
  105. 1998
  106. Lampinen M, Pentikäinen O, Johnson MS, Keinänen K. AMPA receptors and bacterial periplasmic amino acid-binding proteins share the ionic mechanism of ligand recognition. EMBO Journal, 1998, volume 17, pages: 4704-4711.
  107. Suoniemi A, Tanskanen J, Pentikäinen O, Johnson MS, Schulman AH. The core domain of retrotransposon integrase in Hordeum: predicted structure and evolution. Molecular Biology and Evolution, 1998, volume 15, pages: 1135-1144.